Becton Dickinson & (BDX) Stock
Global medical technology firm supplying hospitals and laboratories. Here's the price, business snapshot, and what's worth knowing about Becton Dickinson & in October 2026.
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It’s Moving
BDX Shares Rally 25.5% on Execution Strength and Portfolio Reshaping
- Stronger execution metrics have fueled a 25.5% gain in BDX shares over the last six months.
- The company is actively reshaping its portfolio and investing in U.S. manufacturing to mitigate tariff impacts.
- Product innovation continues to drive value, helping offset cost pressures that affect the wider industry.
BDX Shares Rally 25.5% on Execution Strength and Portfolio Reshaping
- Stronger execution metrics have fueled a 25.5% gain in BDX shares over the last six months.
- The company is actively reshaping its portfolio and investing in U.S. manufacturing to mitigate tariff impacts.
- Product innovation continues to drive value, helping offset cost pressures that affect the wider industry.
Sixth Month Growth Performance
When is the next earnings date for BECTON DICKINSON & CO (BDX)?
BDX has a confirmed upcoming earnings report scheduled for November 5, 2026, before market opens. This release will cover the company's third-quarter fiscal results for the period ending in late September 2026. The timing aligns with the typical reporting cycle observed in recent quarters, maintaining consistency with historical disclosure patterns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton Dickinson's stock, expecting it to rise significantly in value.
Financial Health
Becton Dickinson is showing strong revenue and profitability, with healthy cash flow generation.
Dividend
Becton Dickinson's dividend yield of 2.11% is reasonable for those seeking some income from their investment. If you invested $1000 you would be paid $21.10 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
